File Clinical Trial Applications for the 755-201-EB trial
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 11 Jan 2021
- Due
- 30 Jun 2021
- Delivered
- 28 Apr 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“File CTAs in 1H21”
What we found
Evidence strength A What the grades mean
The company announced the filing of initial Clinical Trial Applications for the 755-201-EB trial on April 28, 2021, within the first half of the year, with additional applications submitted shortly thereafter.
-
A InMed Pharmaceuticals Inc. 10-K filed 2021-09-24
“April 28, 2021 – We announced that we filed Clinical Trial Applications (“CTAs”) in Austria, Israel and Serbia as part of a Phase 2 clinical trial of INM-755 (cannabinol) cream in Epidermolysis Bullosa (“EB”).” ✓ confirmed on the page
-
A InMed Pharmaceuticals Inc. 10-K filed 2021-09-24
“Regulatory applications to support this global trial have been filed and are under review by the National Competent Authorities and Ethics Committees in Germany, France, Italy, Austria, Israel, Greece and Serbia” ✓ confirmed on the page
Market reaction: the shares moved +1.6% against the S&P 500 over the three sessions around the disclosure (23 Sep 2021 to 28 Sep 2021). What this measures
Checked 24 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Regulatory other
- Indicative materiality
- Medium rules
- Action
- File
- Deliverable
- Clinical Trial Applications for 755-201-EB trial
- In the company’s control
- High
- Specificity
- High
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you InMed Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-INM-021653 · Corrections policy